Vaccine, Singapore (SG)
Vaccine, Singapore (SG) @singaporevaccine_com: vaccine jab/shot/injection schedule, to vaccinate against the infection, to immunise against infectious disease, Singapore. Private and confidential service. Definitions, references, and latest news.
Vaccine types available for vaccination / immunisation (uk) / immunization (us) :
|Vaccine ||Against ||Disease ||Age ||D |
|Dose schedule ||Price |
|MMR vaccine || || ||≥12m ||1 || ||$70/= |
| ||Measles virus ||Measles |
| ||Mumps virus ||Mumps |
| ||Rubella virus ||Rubella |
| Varilrix™ || Varicella zoster virus |
| Varicella Chickenpox ||12m-12y ||1 || ||$121/= |
|≥13y ||2 ||6-10w interval |
| Zostavax™ || Herpes zoster Shingles ||≥50y ||1 || ||$295/= |
|Stamaril® ||Yellow fever virus ||Yellow fever ||9m-59y ||1 ||10 yearly ||$250/= |
|Inactivated / Whole / Viral & Bacterial|
|Rabipur® ||Rabies virus ||Rabies ||any ||3 ||d 0, 7, & 21 or 28 ||$call/= |
|Ixiaro® ||Japanese encephalitis virus ||Japanese encephalitis ||≥17y ||2 ||2nd: 28d after 1st ||$386/= |
|1 ||Booster: 12-24m after 2nd |
|Dukoral® ||Vibrio cholerae ||Cholera ||2-6y ||3 ||1-6w interval ||$113/= |
|1 ||Booster: 6m after 3rd |
|≥6y ||2 ||1-6w interval|
|1 ||Booster: 2y after 2nd |
|Inactivated / Fractional / Protein |
| Intanza™ ||Influenza virus ||Influenza ||18-59y ||1 ||1 yearly ||$30/= |
| Fluarix™ ||Influenza virus ||Influenza ||6-36m ||½ ||1 yearly ||$30/= |
|>3y ||1 |
| Tetavax ||Clostridium tetani ||Tetanus ||adults ||3 ||1-2m interval |
3rd @ 6-12m
|booster ||1 ||10 yearly |
|Boostrix® || || ||≥4y ||1 ||<10 yearly ||$70/= |
| ||Corynebacterium diphtheriae ||Diphtheria |
| ||Clostridium tetani ||Tetanus |
| ||Bordetella pertussis ||Pertussis |
|Inactivated / Fractional / Polysaccharide / Pure|
| Typhim Vi® ||Salmonella typhi ||Typhoid fever ||>5y ||1 ||3 yearly ||$48/= |
| Mencevax® ACWY ||Neisseria meningitidis |
types A, C, W-135
|Meningococcal meningitis ||>2y ||1 || ||$80/= |
|Inactivated / Fractional / Polysaccharide / Conjugate|
| Menactra® ||Neisseria meningitidis |
types A, C, W-135
|Meningococcal meningitis ||2-55y ||1 || ||$195/= |
| Prevenar 13® (SG) / |
Prevnar 13® (US)
|Streptococcus pneumoniae |
types 1, 3, 4, 5,
6A, 6B, 7F, 9V, 14,
18C, 19A, 19F, 23F
|Pneumococcal infection ||6w-6m ||4 ||1m interval |
4th @ 12-15m
|7-11m ||2 ||1m interval |
|12-23m ||2 ||2m interval |
|2-5y ||1 |
|≥50y ||1 |
If the clinic attendance is just for vaccination alone, no additional consultation fees are charged.
Testing for immunity against the following is available:
Other vaccines not stocked References
| Advertisement: Come to sunny Singapore to have your testing and treatment. Singapore Ministry of Health registered general practice (GP) clinic: |
| SHIM CLINIC|
168 Bedok South Avenue 3 #01-473
Tel: (+65) 6446 7446
Fax: (+65) 6449 7446
24hr Answering Tel: (+65) 6333 5550
Web: Vaccine, Singapore (SG)
| Opening Hours |
Monday to Friday: 9 am to 3 pm, 7 pm to 11 pm
Saturday & Sunday: 7 pm to 11 pm
Public Holidays: Closed
Last registration: one hour before closing time.
Walk-in clinic. Appointments not required.
Bring NRIC, Work Pass or Passport for registration.
Immune mechanisms of vaccine induced protection against chronic hepatitis C virus infection in chimpanzees.
Wed, 28 Jan 2015 18:48:21 +0100 | World Journal of Hepatology
We describe the results of the individual vaccine evaluation experiments in chimpanzees, in relation to what has been observed in humans. The results of the different studies indicate that partial protection against infection can be achieved, but a clear correlate of protection has thus far not yet been defined.
2012/13 influenza vaccine effectiveness against hospitalised influenza A(H1N1)pdm09, A(H3N2) and B: estimates from a European network of hospitals.
Wed, 28 Jan 2015 17:05:03 +0100 | Euro Surveill
Authors: Rondy M, Launay O, Puig-Barbera J, Gefenaite G, Castilla J, de Gaetano Donati K, Galtier F, Hak E, Guevara M, Costanzo S, European hospital IVE network, Moren A
Assessing the risk of measles resurgence in a highly vaccinated population: Belgium anno 2013.
Wed, 28 Jan 2015 17:05:03 +0100 | Euro Surveill
Authors: Hens N, Abrams S, Santermans E, Theeten H, Goeyvaerts N, Lernout T, Leuridan E, Van Kerckhove K, Goossens H, Van Damme P, Beutels P
Nigeria: Court Pronouncement On Abalaka's HIV Vaccine Misleading - Nepwhan
Wed, 28 Jan 2015 12:11:17 +0100 | AllAfrica News: HIV-Aids and STDs
[Vanguard]ABUJA: Following what it described as the 'misleading' court pronouncement in regards to the Dr. Jeremiah Abalaka's HIV vaccine, the Network of People Living With HIV/AIDS (NEPWHAN) has called on Attorney General of Federation and Minister of Justice and other co-defendants in the suite to appeal the judgment and to stay action on the execution of the pronouncement. (Source: AllAfrica News: HIV-Aids and STDs)
Nigeria: Abalaka - Court Ruling Spells Doom for Persons With HIV - Nepwhan
Wed, 28 Jan 2015 11:32:15 +0100 | AllAfrica News: HIV-Aids and STDs
[Daily Trust]The Network of People living with HIV/AIDS in Nigeria (NEPWHAN) and several civil societies organisations have raised the alarm over the recent court ruling in Makurdi, Benue State which lifted the ban on Dr Jeremiah Abalaka to proceed in his production of vaccines against HIV/AIDS. (Source: AllAfrica News: HIV-Aids and STDs)
Global estimates of prevalent and incident herpes simplex virus type 2 infections in 2012.
Wed, 28 Jan 2015 07:10:08 +0100 | Herpes
CONCLUSIONS: The global burden of HSV-2 infection is large, leaving over 400 million people at increased risk of genital ulcer disease, HIV acquisition, and transmission of HSV-2 to partners or neonates. These estimates highlight the critical need for development of vaccines, microbicides, and other new HSV prevention strategies.
Customized soap bubbles set to transform drug and vaccine delivery
Wed, 28 Jan 2015 05:00:00 +0100 | EurekAlert! - Infectious and Emerging Diseases
(University of Maryland) At a University of Maryland start-up called SD Nanosciences, scientists are covering soap bubbles with biomolecules that act as a disguise, tricking the body's cells into mistaking the capsule for a bacterium, a cancer cell or almost any other disease-causing cell. Because the technology is flexible, cost-effective and highly efficient, it is drawing a lot of attention from both public and private funders for drug delivery and vaccine production. (Source: EurekAlert! - Infectious and Emerging Diseases)
Insulated Isothermal Reverse Transcriptase PCR (iiRT‐PCR) for Rapid and Sensitive Detection of Classical Swine Fever Virus
Wed, 28 Jan 2015 01:21:12 +0100 | Transboundary and Emerging Diseases
In this study, we describe validation of a new probe‐based insulated isothermal reverse transcriptase PCR (iiRT‐PCR) assay for rapid detection of classical swine fever virus (CSFV) on a compact, user‐friendly device (POCKIT™ Nucleic Acid Analyzer) that does not need data interpretation by the user. The assay accurately detected CSFV RNA from a diverse panel of 33 CSFV strains representing all three genotypes plus an additional in vitro‐transcribed RNA from cloned sequences representing a vaccine strain. No cross‐reactivity was observed with a panel of 18 viruses associated with livestock including eight other pestivirus strains (bovine viral diarrhoea virus type 1 and type 2, border disease virus, HoBi atypical pestivirus), African swine fever virus, swine vesicular disease vi...
Seroprevalence of Rift Valley fever virus infection in camels (dromedaries) in northern Tanzania
Wed, 28 Jan 2015 01:20:50 +0100 | Tropical Animal Health and Production
Syndromic surveillance of peste des petits ruminants and other animal diseases in Koinadugu district, Sierra Leone, 2011–2012
Wed, 28 Jan 2015 01:20:48 +0100 | Tropical Animal Health and Production